Equity investor earns billions on the world's best-selling drugs

Every year, private equity investor Royalty Pharma - that recently acquired the rights to royalties and milestones from two Zealand drugs - earns fortunes from royalties from the world's top-selling therapies, including the inflammation drug Humira.

Photo: Zealand Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles